ORLANDO — An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual Meeting and Exposition.
The first four patients treated with KLN-1010 (Kelonia Therapeutics) achieved early minimal residual disease-negative response by 1 month and responses deepened over time, data from the phase 1 inMMyCAR study showed.
The two patients with the longest follow-up sustained MRD-negative bone marrow responses through 3 months. Memory phenotype T cells persisted in the